{"id":"darunavir-drv-r","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darunavir binds to the active site of HIV protease with high affinity, inhibiting the enzyme's ability to process viral precursor proteins into functional structural and enzymatic proteins. This prevents the formation of mature, infectious viral particles. It is typically administered with ritonavir (a CYP3A4 inhibitor) to boost plasma concentrations and improve efficacy.","oneSentence":"Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:13.877Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients"},{"name":"HIV-1 infection in treatment-naïve patients (in combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT02738502","phase":"PHASE2","title":"Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-07-06","conditions":"Maternal-fetal Infection Transmission","enrollment":91},{"nctId":"NCT02383108","phase":"PHASE2, PHASE3","title":"Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-06","conditions":"HIV Infection","enrollment":318},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT01792570","phase":"PHASE3","title":"DRV/r + RPV QD: Efficacy and Toxicity Reduction","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2014-09-30","conditions":"Human Immunodeficiency Virus","enrollment":37},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01258374","phase":"","title":"Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-05","conditions":"Integrase Inhibitors, HIV; HIV PROTEASE INHIB","enrollment":15},{"nctId":"NCT01900106","phase":"PHASE3","title":"A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)","status":"COMPLETED","sponsor":"University of Modena and Reggio Emilia","startDate":"2013-11","conditions":"HIV Infection","enrollment":47},{"nctId":"NCT03892161","phase":"PHASE1","title":"Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2018-04-12","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT03589027","phase":"PHASE2","title":"Darunavir and Rilpivirine Interactions With Levonorgestrel Implant","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-08-07","conditions":"HIV-1-infection, Contraception","enrollment":60},{"nctId":"NCT03589040","phase":"PHASE2","title":"Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2018-09-25","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02337322","phase":"PHASE4","title":"Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2015-03-31","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":104},{"nctId":"NCT02671383","phase":"PHASE3","title":"Evaluation of Low-dose Darunavir in a Switch Study","status":"COMPLETED","sponsor":"Willem Daniel Francois Venter","startDate":"2016-06-30","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT02926456","phase":"","title":"Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2016-07-22","conditions":"Human Immunodeficiency Virus","enrollment":337},{"nctId":"NCT01449929","phase":"PHASE3","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-10-31","conditions":"Infection, Human Immunodeficiency Virus","enrollment":488},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT01905059","phase":"PHASE3","title":"Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-02","conditions":"HIV Infection","enrollment":265},{"nctId":"NCT00543101","phase":"PHASE4","title":"Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2007-10","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT01374802","phase":"PHASE1","title":"Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT01258439","phase":"PHASE4","title":"Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2010-11","conditions":"HIV, Cardiovascular Disease","enrollment":25},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT00517192","phase":"PHASE3","title":"Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT02097381","phase":"NA","title":"Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2010-04","conditions":"HIV Infection","enrollment":10},{"nctId":"NCT01541085","phase":"","title":"An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2011-12","conditions":"Human Immunodeficiency Virus; HIV","enrollment":33},{"nctId":"NCT01391013","phase":"PHASE2","title":"A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2009-06","conditions":"Human Immunodeficiency Virus 1","enrollment":30},{"nctId":"NCT00458302","phase":"PHASE3","title":"Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2007-06","conditions":"HIV Infections, AIDS Virus, Human Immunodeficiency Virus","enrollment":256},{"nctId":"NCT01323257","phase":"PHASE1","title":"TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-03","conditions":"Hepatitis C Virus","enrollment":49},{"nctId":"NCT00765154","phase":"PHASE4","title":"NNRTI/PI Toxicity Switch to Darunavir Study","status":"TERMINATED","sponsor":"St Stephens Aids Trust","startDate":"2008-10","conditions":"HIV","enrollment":12},{"nctId":"NCT00460382","phase":"PHASE2","title":"Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":266,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Darunavir (DRV/r)","genericName":"Darunavir (DRV/r)","companyName":"Community Research Initiative of New England","companyId":"community-research-initiative-of-new-england","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients (in combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}